EU/3/16/1744: Orphan designation for the treatment of periventricular leukomalacia

Autologous mononuclear cells derived from human cord blood

Table of contents

Overview

On 14 October 2016, orphan designation (EU/3/16/1744) was granted by the European Commission to BrainRepair UG (haftungsbeschränkt), Germany, for autologous mononuclear cells derived from human cord blood for the treatment of periventricular leukomalacia.

Key facts

Active substance
Autologous mononuclear cells derived from human cord blood
Intented use
Treatment of periventricular leukomalacia
Orphan designation status
Positive
EU designation number
EU/3/16/1744
Date of designation
14/10/2016
Sponsor
BrainRepair UG (haftungsbeschränkt)
Universitätsstr. 140
44799 Bochum
Germany
Tel. +49 234 5881 960
Fax +49 234 5881 9619
E-mail: arne.jensen@brainrepair.eu

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
Average
1 rating